Business
AI summaryXbrane Biopharma AB is a biotechnology company engaged in the development, manufacture, and sale of biosimilars. Its products include Ximluci, a ranibizumab biosimilar used to treat eye conditions such as wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion, while its pre-clinical pipeline includes Xdivane, a nivolumab (PD-1 inhibitor) biosimilar for various cancers, and Xdarzane, a daratumumab biosimilar targeting CD38 for multiple myeloma. The company has a strategic partnership with JOINN Biologics for development services on Xdarzane. Xbrane Biopharma was incorporated in 2008 and is headquartered in Solna, Sweden.
